Novo Nordisk wins EU agency backing for new insulin
LONDON/COPENHAGEN (Reuters) – Novo Nordisk’s ultra long-acting insulin Tresiba has been recommended for approval by the European Medicines Agency in an important boost for the Danish drugmaker’s key new product. The European endorsement, announced by the London-based agency and the company on Friday, follows regulatory delays for the diabetes treatment in the United States, where the bulk of future sales are expected to be generated. …